Search filters

List of works by Giuliana Alimena

"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia

scientific article

5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials ⬇️

scientific article published on February 21, 2012

AIDA treatment for high-risk acute promyelocytic leukemia in a pregnant woman at 21 weeks of gestation

scientific article

Absence of chromosome heterogeneity between classical Fanconi's anemia and the Estren-Dameshek type

Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease

scientific article

Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

scientific article published on June 1, 2011

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

scientific article

Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

scientific article published on 27 March 2012

Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia

scientific article

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms

scientific article

Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response ⬇️

scientific article published on January 11, 2012

Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib ⬇️

scientific article published on May 29, 2013

Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment

scientific article published on 12 October 2014

Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?

scientific article published on 16 July 2009

Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation ⬇️

scientific article published on March 20, 2013

Azacitidine followed by radiotherapy as effective treatment for chronic myelomonocytic leukemia with extramedullary localization ⬇️

scientific article published on July 9, 2012

Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy

scientific article published on 03 July 2014

Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN.

scientific article

Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors

scientific article

Can nifedipine and estrogen interaction with imatinib be responsible for gallbladder stone development?

scientific article published in July 2005

Can we safely discontinue imatinib? Searching for new endpoints in CML: A standardized definition of “cure” ⬇️

scientific article published on September 29, 2012

Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience

scientific article published in October 2007

Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC).

scientific article

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion

scientific article published on 17 May 2010

Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib

scientific article

Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase

scientific article published on 16 August 2015

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

scientific article published on 06 October 2008

Chronic myelomonocytic leukemia treatment with azacitidine: What have we learned so far? ⬇️

scientific article published on November 20, 2012

Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation

scientific article published in January 2005

Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution

scientific article published in November 2004

Clofarabine-Based Regimen as Useful Bridge Therapy for Allogeneic Transplantation in Myeloid Blast Crisis of Philadelphia-Positive Chronic Myeloid Leukemia Resistant to Imatinib and Dasatinib ⬇️

scientific article published on October 11, 2010

Cocaine abuse may influence the response to imatinib in CML patients

scientific article published in March 2007

Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients

scientific article published in September 2009

Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment

scientific article published in January 2006

Comparison of JAK2(V617F) -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology

scientific article

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

scientific article

Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia

scientific article published on 28 November 2012

Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy

scientific article published on 30 March 2010

Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront

scientific article published on 9 February 2015

Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.

scientific article published on 17 December 2013

Cutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib

scientific article published on 20 February 2016

Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen

scientific article published in January 2002

Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose

scientific article published in June 2010

Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life

scientific article published in June 2010

Dasatinib first-line: Multicentric Italian experience outside clinical trials

scientific article

Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localizations

scientific article published on 14 March 2009

Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance

scientific article

Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results

scientific article published on 22 August 2009

Deferasirox treatment for myelodysplastic syndromes: “real-life” efficacy and safety in a single-institution patient population ⬇️

scientific article published on May 9, 2012

Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response

scientific article published on 9 July 2010

Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis

scientific article published on 3 May 2010

Diabetes insipidus as first manifestation of acute myeloid leukaemia with EVI-1-positive, 3q21q26 syndrome and T cell-line antigen expression: what is the EVI-1 gene role?

scientific article published on August 2002

Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia

scientific article published in December 2008

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

scientific article

Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response

scientific article published on 22 May 2015

Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia

scientific article published on 04 February 2014

Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease.

scientific article published in May 2002

Early and late complications related to central venous catheters in hematological malignancies: a retrospective analysis of 1102 patients

scientific article published on 14 February 2014

Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.

scientific article published on 16 January 2007

Early molecular response in chronic myeloid leukemia and halving time: Latest evidences

scientific article

Efficacy and safety of deferasirox in myelodysplastic syndromes

scientific article published on 17 February 2013

Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase

scientific article published on 31 May 2016

Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment

scientific article published in March 2005

Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes

scientific article

Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients

scientific article published in July 2010

Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes ⬇️

scientific article published on October 1, 2011

Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib

scientific article published in April 2004

Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes ⬇️

scientific article published on May 24, 2012

Firstline treatment for chronic phase chronic myeloid leukemia patients should be based on a holistic approach

scientific article published on 28 November 2014

Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia

scientific article published on September 2016

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

article by Gabriele Gugliotta et al published 26 May 2011 in Blood

Haematological improvement as a beneficial effect during deferasirox treatment in transfusion-dependent patients with myelodysplastic syndrome ⬇️

scientific article published on April 15, 2013

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

scientific article

Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy

scientific article

How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety

scientific article published on 27 May 2016

How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: Unmet needs, pitfalls and advantages ⬇️

scientific article published on March 23, 2012

How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review

scientific article

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

scientific article published on 27 August 2016

Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up

scientific article published in May 2010

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

scientific article published in August 2013

Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?

scientific article

Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

scientific article published on 10 October 2012

Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia

scientific article published on 9 December 2015

Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?

scientific article published on 27 April 2015

Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib

scientific article published on 19 November 2014

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

scientific article published on 19 July 2012

Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.

scientific article

Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib

scientific article published on 11 February 2011

Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose

scientific article

Isolated myeloid sarcoma without bone marrow involvement

scientific article published on January 1, 2012

Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy

scientific article

Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia

scientific article

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

scientific article published on 25 June 2015

Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase ⬇️

scientific article published on May 16, 2011

MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine ⬇️

scientific article published on February 1, 2012

Management Options for Refractory Chronic Myeloid Leukemia: Considerations for the Elderly ⬇️

scientific article published on July 1, 2013

Management of the 2009 A/H1N1 influenza pandemic in patients with hematologic diseases: a prospective experience at an Italian center

scientific article

Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment

scientific article published on 16 December 2009

Myelodysplastic syndromes in patients under 50 years old: a single institution experience

scientific article

NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia ⬇️

scientific article published on November 1, 2010

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

scientific article

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

scientific article published on 28 July 2016

Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy

scientific article published on 20 September 2007

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

scientific article published on 12 October 2009

Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences ⬇️

scientific article published on August 15, 2011

Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.

scientific article published on June 2009

Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index ⬇️

scientific article published on January 2, 2012

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia

scientific article

Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors ⬇️

scientific article published on 07 March 2013

Ocular side effects in chronic myeloid leukemia patients treated with imatinib

scientific article published on 3 December 2007

Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors

scientific article published on 16 July 2012

Pain and anxiety associated with bone marrow aspiration and biopsy: a prospective study on 152 Italian patients with hematological malignancies ⬇️

scientific article published on February 2, 2011

Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis

scientific article published on 3 June 2016

Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib

scientific article published in January 2005

Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development

scientific article published on September 2010

Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience

scientific article

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib

scientific article published on 26 December 2017

Prognostic features of patients with myelodysplastic syndromes aged < 50 years: update of a single-institution experience ⬇️

scientific article published on July 9, 2012

Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf?

scientific article published on 5 April 2012

Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline

scientific article published on 15 October 2016

Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians

scientific article

Recurrent Sweet's syndrome in acute myeloid leukemia successfully treated with amphotericin B.

scientific article published in April 2004

Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance

scientific article published on 19 March 2010

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib ⬇️

scientific article published on October 1, 2008

Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients

scientific article

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study

scientific article

Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem

scientific article published on March 2009

Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia.

scientific article published in July 2004

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

scientific article published on 11 February 2009

Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine ⬇️

scientific article published on September 25, 2012

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

scientific article published on 4 October 2016

Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia

scientific article

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

scientific article published on 11 March 2016

Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months

scientific article published in April 2010

Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly

Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs

scientific article published on 02 January 2014

Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.

scientific article published on 29 May 2009

Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?

scientific article published on 21 January 2009

Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients

scientific article published on 7 January 2016

Suboptimal response in chronic myeloid leukemia patients treated with imatinib: early identification and new therapeutic challenges

scientific article published on 06 June 2012

Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide ⬇️

scientific article published on January 12, 2011

Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms

article

Systematic review of dasatinib in chronic myeloid leukemia

scientific article

The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose ⬇️

scientific article published on July 1, 2011

The degree of anemia has an impact on survival in myelodysplastic syndrome patients classified with WPSS ⬇️

scientific article published on December 1, 2011

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

scientific article published on 14 January 2009

The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism

scientific article published on July 2009

The pros and cons of new prognostic eutos score for chronic myeloid leukemia patients

scientific article

The role of comorbidities in chronic myeloid leukemia

scientific article

The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era ⬇️

scientific article published on 04 August 2010

Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response

scientific article published in February 2009

Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia.

scientific article

Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data

scientific article

Unusual association of paroxysmal cold hemoglobinuria as the first sign of disease in myelodysplastic patient

scientific article published on 26 May 2009

Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes

scientific article published on 15 August 2005

“To switch or not to switch: That is the question”—More than 10% of ratio @ 3 months: How to treat chronic myeloid leukemia patients with this response? ⬇️

scientific article published on June 24, 2013

Paulina is supported by:

About Paulina

Help